WO2006119107A3 - Sclerostin binding agents - Google Patents
Sclerostin binding agents Download PDFInfo
- Publication number
- WO2006119107A3 WO2006119107A3 PCT/US2006/016441 US2006016441W WO2006119107A3 WO 2006119107 A3 WO2006119107 A3 WO 2006119107A3 US 2006016441 W US2006016441 W US 2006016441W WO 2006119107 A3 WO2006119107 A3 WO 2006119107A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- binding agents
- sclerostin binding
- sclerostin
- binding
- epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Priority Applications (44)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077028092A KR101450888B1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
EA200702402A EA021539B1 (en) | 2005-05-03 | 2006-04-28 | Antibody to sclerostin and use thereof |
AU2006242431A AU2006242431B2 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
JP2008510083A JP5462484B2 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agent |
EP19211623.4A EP3670528B1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
SI200631623T SI1891101T1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
BR122020023315-0A BR122020023315B1 (en) | 2005-05-03 | 2006-04-28 | uses of a sclerostin binding antibody to treat a bone disorder and improve outcome in a mammal undergoing an orthopedic, dental, implant surgery, joint replacement, bone grafting, cosmetic bone surgery, and bone repair |
MX2013011425A MX358705B (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents. |
ES06751903T ES2412857T3 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
DK06751903.3T DK1891101T3 (en) | 2005-05-03 | 2006-04-28 | SCLEROST BINDING AGENTS |
RS20130358A RS52919B (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
BRPI0610197A BRPI0610197B8 (en) | 2005-05-03 | 2006-04-28 | sclerostin binding antibody, process for its production, pharmaceutical composition comprising said antibody and cloning or expression vector |
NZ563539A NZ563539A (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
MEP-2013-358A ME02085B (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
CA2607197A CA2607197C (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
NO20201120A NO346914B1 (en) | 2005-05-03 | 2006-04-28 | Monoclonal antibody and pharmaceutical composition comprising said antibody. |
PL06751903T PL1891101T3 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
PL19211623T PL3670528T3 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
KR1020157026845A KR101653122B1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
CN200680024330.8A CN101287756B (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
MX2007013759A MX2007013759A (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents. |
KR1020137029088A KR20130126752A (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
EP21188463.0A EP3985015A1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
AU2006242476A AU2006242476B2 (en) | 2005-05-03 | 2006-04-28 | Sclerostin epitopes |
EP06751903.3A EP1891101B8 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
KR1020147006101A KR101624809B1 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
TNP2007000406A TNSN07406A1 (en) | 2005-05-03 | 2007-10-31 | Sclerostin binding agents |
IL187106A IL187106A (en) | 2005-05-03 | 2007-11-01 | Sclerostin-binding antibody |
ZA2007/09480A ZA200709480B (en) | 2005-05-03 | 2007-11-02 | Sclerostin binding agents |
NO20076046A NO345294B1 (en) | 2005-05-03 | 2007-11-23 | Sclerostin binding antibody, process for its preparation, pharmaceutical composition and use |
HK08102741.0A HK1108705A1 (en) | 2005-05-03 | 2008-03-10 | Sclerostin binding agents sclerostin |
IL224968A IL224968B (en) | 2005-05-03 | 2013-02-27 | Sclerostin binding agents |
IL224967A IL224967B (en) | 2005-05-03 | 2013-02-27 | Sclerostin binding agents |
HRP20130803TT HRP20130803T1 (en) | 2005-05-03 | 2013-08-22 | Sclerostin binding agents |
CY20151100488T CY1116525T1 (en) | 2005-05-03 | 2015-06-03 | BINDING STRENGTHENING FACTORS |
PH12015501848A PH12015501848A1 (en) | 2005-05-03 | 2015-08-20 | Binding agents |
HUS2000007C HUS2000007I1 (en) | 2005-05-03 | 2020-03-11 | Sclerostin binding agents |
LU00151C LUC00151I2 (en) | 2005-05-03 | 2020-03-16 | |
NL301034C NL301034I2 (en) | 2005-05-03 | 2020-03-16 | romosozumab |
LTPA2020506C LTC1891101I2 (en) | 2005-05-03 | 2020-04-02 | Sclerostin binding agents |
CY2020009C CY2020009I2 (en) | 2005-05-03 | 2020-05-04 | SCLEROSTEIN BINDING FACTORS |
NO2021014C NO2021014I1 (en) | 2005-05-03 | 2021-03-24 | romosozumab |
CY20211101057T CY1124802T1 (en) | 2005-05-03 | 2021-12-02 | SCLEROSTEIN BINDING FACTORS |
NO20230084A NO20230084A1 (en) | 2005-05-03 | 2023-01-31 | Binding effects |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67758305P | 2005-05-03 | 2005-05-03 | |
US60/677,583 | 2005-05-03 | ||
US77684706P | 2006-02-24 | 2006-02-24 | |
US60/776,847 | 2006-02-24 | ||
US78224406P | 2006-03-13 | 2006-03-13 | |
US60/782,244 | 2006-03-13 | ||
US79264506P | 2006-04-17 | 2006-04-17 | |
US60/792,645 | 2006-04-17 | ||
US11/411,003 | 2006-04-25 | ||
US11/411,003 US7592429B2 (en) | 2005-05-03 | 2006-04-25 | Sclerostin-binding antibody |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006119107A2 WO2006119107A2 (en) | 2006-11-09 |
WO2006119107A3 true WO2006119107A3 (en) | 2006-12-28 |
WO2006119107A9 WO2006119107A9 (en) | 2007-09-20 |
Family
ID=36992590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/016441 WO2006119107A2 (en) | 2005-05-03 | 2006-04-28 | Sclerostin binding agents |
Country Status (42)
Families Citing this family (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69942782D1 (en) * | 1998-11-27 | 2010-10-28 | Ucb Sa | Compositions and methods for increasing bone mineralization |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
EA015166B1 (en) * | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Immunogen sclerostin peptides (sost), inducing formation of specific antibodies |
US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
ITMI20050739A1 (en) * | 2005-04-22 | 2006-10-23 | Effebi Spa | VALVE-ACTUATOR CONNECTION PLATE |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
ITTO20050905A1 (en) * | 2005-12-23 | 2007-06-24 | Univ Degli Studi Torino | SYNTHETIC BINDERS THAT CAN TIE THE OCRATOSSIN AND ITS USES |
EP2423226A3 (en) * | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2460828A3 (en) * | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
LT3345607T (en) * | 2006-12-29 | 2023-01-10 | Ossifi-Mab Llc | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
CA2682212C (en) * | 2007-03-20 | 2014-05-06 | Eli Lilly And Company | Anti-sclerostin antibodies |
US7977313B2 (en) * | 2007-04-27 | 2011-07-12 | Affinergy, Inc. | Methods and compositions for promoting localization of pharmaceutically active agents to bone |
TW200902547A (en) * | 2007-04-27 | 2009-01-16 | Genentech Inc | Potent, stable and non-immunosuppressive anti-CD4 antibodies |
US20110097318A1 (en) * | 2007-08-31 | 2011-04-28 | Amgen Inc. | Solid-State Protein Formulation |
US7981415B2 (en) * | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
EP2227256A1 (en) | 2007-12-14 | 2010-09-15 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
NZ588554A (en) * | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AR072001A1 (en) * | 2008-06-03 | 2010-07-28 | Abbott Lab | IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CN102112494A (en) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
WO2010006060A2 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
MX2011008697A (en) * | 2009-02-17 | 2011-11-18 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40. |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
EP2424566A4 (en) * | 2009-05-01 | 2013-07-31 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
US9775819B2 (en) * | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
EP2488658A4 (en) * | 2009-10-15 | 2013-06-19 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
UY32979A (en) * | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
NZ603045A (en) | 2010-04-07 | 2014-11-28 | Abbvie Inc | Tnf-alpha binding proteins |
BR112012026098A2 (en) | 2010-04-16 | 2016-11-22 | Novartis Ag | methods and compositions for improving implant osseointegration. |
HUE033315T2 (en) * | 2010-05-14 | 2017-11-28 | Amgen Inc | High concentration antibody formulations |
AU2011265005B2 (en) | 2010-06-07 | 2015-04-09 | Amgen Inc. | Drug delivery device |
US9617323B2 (en) * | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20130139884A (en) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | Dual variable domain immunoglobulins and uses thereof |
AR083740A1 (en) | 2010-10-27 | 2013-03-20 | Amgen Inc | DKK1 ANTIBODIES (DICKKOPF-1) AND METHODS OF USE |
EP2635694A4 (en) * | 2010-11-02 | 2015-11-11 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
DE20187001T1 (en) | 2010-11-05 | 2021-04-01 | Novartis Ag | METHOD OF TREATMENT OF PSORIASUS ARTHRITIS WITH IL-17 ANTAGONISTS |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
EA201390923A1 (en) * | 2010-12-22 | 2013-12-30 | Сефалон Острэйлиа Пти Лтд. | MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD |
CN103649118A (en) | 2011-03-01 | 2014-03-19 | 安进公司 | Bispecific binding agents |
AU2012236962B2 (en) | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
SI3404041T1 (en) | 2011-04-19 | 2020-11-30 | Amgen Inc. | Method for treating osteoporosis |
EP4074355A1 (en) | 2011-04-20 | 2022-10-19 | Amgen Inc. | Autoinjector apparatus |
RU2668170C2 (en) | 2011-04-25 | 2018-09-26 | Дайити Санкио Компани, Лимитед | Anti-b7-h3-antibody |
US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
WO2013019954A1 (en) * | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
CA2851521C (en) | 2011-10-14 | 2020-09-22 | Amgen Inc. | Injector and method of assembly |
CA2853357A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
UY34411A (en) * | 2011-10-24 | 2013-05-31 | Abbvie Inc | IMMUNO LINKERS AGAINST SCLEROSTINE |
AR088514A1 (en) | 2011-10-24 | 2014-06-18 | Abbvie Inc | BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
CA2858974A1 (en) * | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
CN104159920A (en) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | Dual specific binding proteins directed against il-13 and/or il-17 |
SG10201709018QA (en) | 2012-03-14 | 2017-11-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
EP3626267A1 (en) * | 2012-07-05 | 2020-03-25 | UCB Pharma, S.A. | Treatment for bone diseases |
KR20180008921A (en) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
TWI639449B (en) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | Cassette for an injector |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
BR112015023862A2 (en) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | isolated antibody, isolated nucleic acid molecule, vector, host cell, method of enhancing an immune response, method of treating cancer, pharmaceutical composition, and isolated agonistic antibody |
DK3312195T3 (en) * | 2013-03-20 | 2020-01-06 | Genzyme Corp | METHODS OF TREATING IMPERFECTA OF OSTEOGENESIS |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
US11427627B2 (en) | 2013-09-05 | 2022-08-30 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
CA2920894C (en) | 2013-10-24 | 2023-03-14 | Amgen Inc. | Injector and method of assembly |
CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CN110642944B (en) * | 2014-03-07 | 2021-06-11 | 神州细胞工程有限公司 | Antibody for neutralizing human infected H7N9 influenza A virus and application thereof |
ES2861600T3 (en) | 2014-04-04 | 2021-10-06 | Mayo Found Medical Education & Res | Immunoglobulin isotyping using precise molecular mass |
EP3139977B1 (en) | 2014-05-07 | 2021-02-17 | Amgen Inc. | Autoinjector with shock reducing elements |
EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
WO2015187802A1 (en) | 2014-06-03 | 2015-12-10 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
MA54716A (en) | 2014-10-23 | 2021-11-17 | Amgen Inc | REDUCTION OF THE VISCOSITY OF PHARMACEUTICAL FORMULATIONS |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
ES2785311T3 (en) | 2014-12-19 | 2020-10-06 | Amgen Inc | Mobile button drug delivery device or user interface field |
AR103173A1 (en) | 2014-12-22 | 2017-04-19 | Novarits Ag | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17 |
EP3556411B1 (en) | 2015-02-17 | 2021-06-30 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
MX2017011480A (en) * | 2015-03-13 | 2018-04-24 | Jiangsu Hengrui Medicine Co | Anti-sclerostin antibody, antigen binding fragment and medical use thereof. |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3722318A1 (en) | 2015-07-06 | 2020-10-14 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
ES2755717T3 (en) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinjector with signaling cap |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
EP4043492A1 (en) | 2016-03-01 | 2022-08-17 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
ES2814287T3 (en) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reduce the likelihood of glass breakage in drug delivery devices |
LT3219727T (en) * | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
JP7309363B2 (en) | 2016-05-13 | 2023-07-18 | アムジエン・インコーポレーテツド | vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
AU2017310412A1 (en) | 2016-08-08 | 2019-02-21 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
JP6918808B2 (en) * | 2016-08-31 | 2021-08-11 | 栄研化学株式会社 | Antibody measurement method using antigen-supporting insoluble carrier particles in which antigens are immobilized by different methods, reagents for antibody measurement |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
US11414482B2 (en) | 2016-11-08 | 2022-08-16 | University Of Miami | Anti-secretogranin III (SCG3) antibodies and uses thereof |
KR20220051269A (en) | 2016-12-21 | 2022-04-26 | 메레오 바이오파마 3 리미티드 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
JP2020502218A (en) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ 3 リミテッド | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
MX2019009625A (en) | 2017-02-17 | 2019-10-09 | Amgen Inc | Drug delivery device with sterile fluid flowpath and related method of assembly. |
MX2019009755A (en) | 2017-02-17 | 2019-10-07 | Amgen Inc | Insertion mechanism for drug delivery device. |
AU2018231107B2 (en) | 2017-03-06 | 2023-04-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
WO2018164829A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
MX2019010671A (en) | 2017-03-09 | 2019-10-21 | Amgen Inc | Insertion mechanism for drug delivery device. |
CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
EA037969B1 (en) | 2017-03-28 | 2021-06-17 | Эмджен Инк. | Plunger rod and syringe assembly system and method |
CN110799541A (en) * | 2017-04-27 | 2020-02-14 | 特沙诺有限公司 | Antibody agents against lymphocyte activation gene-3 (LAG-3) and uses thereof |
WO2018201064A1 (en) | 2017-04-28 | 2018-11-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
CN110709121B (en) | 2017-06-08 | 2022-06-24 | 安进公司 | Torque-driven drug delivery device |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MA49447A (en) | 2017-06-22 | 2020-04-29 | Amgen Inc | REDUCTION OF IMPACTS / SHOCKS OF ACTIVATION OF A DEVICE |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
MA49562A (en) | 2017-07-14 | 2020-05-20 | Amgen Inc | NEEDLE INSERTION-RETRACTION SYSTEM FEATURING A DOUBLE-TORSION SPRING SYSTEM |
MA49626A (en) | 2017-07-21 | 2020-05-27 | Amgen Inc | GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
MX2020000582A (en) * | 2017-07-27 | 2020-09-10 | Jiangsu Hengrui Medicine Co | Sost antibody pharmaceutical composition and uses thereof. |
SG11202000727SA (en) | 2017-08-01 | 2020-02-27 | Amgen Inc | Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry |
CA3071636A1 (en) | 2017-08-01 | 2019-02-07 | Amgen Inc. | Systems and methods for performing a real-time glycan assay of a sample |
MA49838A (en) | 2017-08-09 | 2020-06-17 | Amgen Inc | DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US11788093B2 (en) | 2017-09-07 | 2023-10-17 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptor t-cells expressing interleukin-8 receptor |
EP3681528A4 (en) | 2017-09-13 | 2021-07-21 | Mayo Foundation for Medical Education and Research | Identification and monitoring of apoptosis inhibitor of macrophage |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
MA50348A (en) | 2017-10-09 | 2020-08-19 | Amgen Inc | DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE |
MA50528A (en) | 2017-11-03 | 2020-09-09 | Amgen Inc | SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
CN111263651B (en) | 2017-11-16 | 2022-06-17 | 安进公司 | Auto-injector with pause and end point detection |
MA50904A (en) | 2017-11-16 | 2020-09-23 | Amgen Inc | NEEDLE INSERTION MECHANISM FOR DRUG DELIVERY DEVICE |
MA52013A (en) | 2018-03-13 | 2021-01-20 | Amgen Inc | METHODS FOR PREPARING TRYPSIN RESISTANT POLYPEPTIDES FOR MASS SPECTROMETRY ANALYSIS |
SG11202008869UA (en) | 2018-03-13 | 2020-10-29 | Amgen Inc | Sequential digestion of polypeptides for mass spectrometric analysis |
JP2021519068A (en) | 2018-03-26 | 2021-08-10 | アムジェン インコーポレイテッド | Total non-fucosylated glycoform of antibodies produced in cell culture |
KR20200138254A (en) | 2018-03-30 | 2020-12-09 | 암젠 인크 | C-terminal antibody variant |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
JOP20200343A1 (en) | 2018-07-02 | 2020-12-31 | Xencor Inc | Anti-steap1 antigen-binding protein |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MA53375A (en) | 2018-07-24 | 2021-06-02 | Amgen Inc | ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES |
US20210369982A1 (en) | 2018-07-24 | 2021-12-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
KR20210043607A (en) | 2018-08-10 | 2021-04-21 | 암젠 인크 | Method for preparing antibody pharmaceutical formulation |
JP2022500095A (en) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | Intervention dosing system and method |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
US20200101229A1 (en) | 2018-10-02 | 2020-04-02 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
AR116607A1 (en) | 2018-10-05 | 2021-05-26 | Amgen Inc | DRUG ADMINISTRATION DEVICE WITH DOSE INDICATOR |
BR112021007016A2 (en) | 2018-10-15 | 2021-07-13 | Amgen Inc. | drug delivery device having damping mechanism |
EA202191038A1 (en) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | METHOD OF PLATFORM ASSEMBLY FOR MEDICINE DELIVERY DEVICE |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MA54048A (en) | 2018-11-01 | 2022-02-09 | Amgen Inc | DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY |
US20220146413A1 (en) | 2018-12-14 | 2022-05-12 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
WO2020168156A1 (en) | 2019-02-14 | 2020-08-20 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
JP2022521200A (en) | 2019-02-20 | 2022-04-06 | アムジエン・インコーポレーテツド | How to determine protein stability |
EP3935396A1 (en) | 2019-03-04 | 2022-01-12 | Amgen Inc. | In vivo reversibility of high molecular weight species |
CN109897105B (en) * | 2019-03-22 | 2022-05-20 | 天承南运(天津)科技有限公司 | Monoclonal antibody of EV71 virus, preparation method and detection test strip thereof |
CA3133459A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
EP3958934A1 (en) | 2019-04-24 | 2022-03-02 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
MA56121A (en) | 2019-06-05 | 2022-04-13 | Amgen Inc | METHODS FOR IDENTIFYING THERAPEUTIC PROTEIN ATTRIBUTES |
JP2022544495A (en) | 2019-08-12 | 2022-10-19 | アムジエン・インコーポレーテツド | Anti-sclerostin antibody formulation |
JP2022545227A (en) | 2019-08-23 | 2022-10-26 | アムジエン・インコーポレーテツド | Drug delivery device with configurable needle shield-engaging component and related methods |
CN110499287B (en) * | 2019-08-30 | 2021-07-23 | 博雅干细胞科技有限公司 | Method for simply preparing placenta mesenchymal stem cell exosome |
BR112022005583A2 (en) | 2019-09-26 | 2022-09-20 | Amgen Inc | METHODS FOR PRODUCTION OF ANTIBODY COMPOSITIONS |
AU2021264094A1 (en) * | 2020-04-30 | 2022-11-24 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
CN111537737B (en) * | 2020-05-18 | 2023-05-12 | 巴迪泰(广西)生物科技有限公司 | Procalcitonin and C-reactive protein combined detection kit |
EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
US20230349912A1 (en) | 2020-09-18 | 2023-11-02 | Amgen Inc. | Methods of processing a sample for peptide mapping analysis |
US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
MX2023005320A (en) | 2020-11-05 | 2023-05-19 | Amgen Inc | Materials and methods for protein processing. |
KR102255372B1 (en) | 2020-11-24 | 2021-05-25 | (주)발맥스기술 | Portable BOG Heat Exchanging Apparatus |
AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
AR126089A1 (en) | 2021-06-07 | 2023-09-13 | Amgen Inc | USE OF FUCOSIDASE TO CONTROL THE LEVEL OF AFFUCOSYLATION OF GLUCOSYLATED PROTEINS |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023086793A1 (en) | 2021-11-09 | 2023-05-19 | Amgen Inc. | Production of therapeutic proteins |
WO2023179791A1 (en) * | 2022-03-24 | 2023-09-28 | Angitia Biomedicines Limited | Treatment of musculoskeletal disorders |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04141095A (en) * | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | Hiv-resistant recombined modified antibody and method for preparing modified antibody |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
WO2000032773A1 (en) * | 1998-11-27 | 2000-06-08 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
WO2005003158A2 (en) * | 2003-06-16 | 2005-01-13 | Celltech R & D, Inc. | Compositions and methods for increasing bone mineralization |
WO2005014650A2 (en) * | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US32011A (en) | 1861-04-09 | Coffee-pot | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4427115A (en) * | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
USRE32011E (en) * | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
JPS58117537A (en) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | Photosensitive resin composition |
JPS5955608A (en) * | 1982-09-24 | 1984-03-30 | Hitachi Ltd | Amplifier |
US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (en) * | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Device for the quantitative and qualitative detection of hydrocarbon-containing suspended particles in gases |
US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) * | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (en) * | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | Stable aqueous liposome suspension |
CA2090126C (en) * | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
JP2958076B2 (en) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
CA2094608A1 (en) | 1990-10-22 | 1992-04-23 | John D. Taylor | Dna construct for providing rna therapy |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
KR100249937B1 (en) * | 1991-04-25 | 2000-04-01 | 나가야마 오사무 | Reshaped human antibody to human interleukin-6 receptor |
CA2164505A1 (en) * | 1993-06-07 | 1994-12-22 | Phillip W. Berman | Hiv envelope polypeptides |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
DE4427221A1 (en) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induced osteoclast modulation for osteoporosis therapy |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220912A1 (en) * | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
US5738868A (en) * | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US6207153B1 (en) * | 1996-05-22 | 2001-03-27 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6673901B2 (en) * | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
EP1000152A2 (en) | 1997-08-01 | 2000-05-17 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
US6815201B2 (en) * | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
GB9818881D0 (en) | 1998-08-28 | 1998-10-21 | Glaxo Group Ltd | Compounds |
US6544485B1 (en) * | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
ES2331657T3 (en) | 1999-06-09 | 2010-01-12 | Genentech, Inc. | METHODS FOR TUMORS DIAGNOSIS. |
JP4141095B2 (en) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | Semiconductor device and manufacturing method thereof |
EP1266000A1 (en) | 2000-03-02 | 2002-12-18 | Amgen Inc. | Chordin-like-2 molecules and uses thereof |
CA2410912A1 (en) * | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
JP2004520005A (en) | 2000-06-19 | 2004-07-08 | エフ.ホフマン−ラ ロシュ アーゲー | Osteolevin gene polymorphism |
JP4451059B2 (en) | 2000-09-01 | 2010-04-14 | ジェネンテック インコーポレイテッド | Secreted and transmembrane polypeptides and nucleic acids encoding them |
DE60139944D1 (en) | 2000-10-12 | 2009-10-29 | Genentech Inc | LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (en) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA · 1 · -pyrrolines |
EP1436329A4 (en) * | 2001-09-20 | 2005-04-27 | Alexion Pharma Inc | Anti-pdgf antibodies and methods for producing engineered antibodies |
AUPR837201A0 (en) | 2001-10-19 | 2001-11-15 | BUKILIC, Aleksandar | Method and apparatus for cleaning and disinfecting a toothbrush |
BR0214680A (en) | 2001-12-06 | 2006-05-30 | Biocontrol Systems Inc | sample collection and testing system |
US20030186915A1 (en) * | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
US7332276B2 (en) * | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
FR2838379B1 (en) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | DEVICE FOR PURIFYING THE AIR OF THE CABIN OF A MOTOR VEHICLE |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
DE10255152A1 (en) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | pollutant sucker |
US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) * | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
US7226902B2 (en) | 2003-03-14 | 2007-06-05 | Celltech R&D, Inc. | Ligands for TGF-beta binding proteins and uses thereof |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (en) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT |
WO2005018912A1 (en) * | 2003-07-21 | 2005-03-03 | Alpla-Werke Alwin Lehner Gmbh & Co. Kg | Method for producing a preform for plastic bottles |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
LT3345607T (en) | 2006-12-29 | 2023-01-10 | Ossifi-Mab Llc | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
WO2008092894A1 (en) | 2007-02-02 | 2008-08-07 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
CA2682212C (en) | 2007-03-20 | 2014-05-06 | Eli Lilly And Company | Anti-sclerostin antibodies |
CL2008002775A1 (en) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
CN101951954A (en) | 2007-11-02 | 2011-01-19 | 诺瓦提斯公司 | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
EP2227256A1 (en) | 2007-12-14 | 2010-09-15 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
AR072001A1 (en) | 2008-06-03 | 2010-07-28 | Abbott Lab | IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
AR075715A1 (en) | 2009-03-05 | 2011-04-20 | Novartis Ag | FORMULATION OF LIOFILIZED ANTIBODY |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
HUE033315T2 (en) * | 2010-05-14 | 2017-11-28 | Amgen Inc | High concentration antibody formulations |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
AR083740A1 (en) | 2010-10-27 | 2013-03-20 | Amgen Inc | DKK1 ANTIBODIES (DICKKOPF-1) AND METHODS OF USE |
CN103649118A (en) * | 2011-03-01 | 2014-03-19 | 安进公司 | Bispecific binding agents |
AU2012236962B2 (en) * | 2011-03-25 | 2017-05-11 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
WO2013019954A1 (en) * | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
CA2858974A1 (en) * | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
UY35148A (en) * | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
KR20200138254A (en) * | 2018-03-30 | 2020-12-09 | 암젠 인크 | C-terminal antibody variant |
-
2006
- 2006-04-25 US US11/411,003 patent/US7592429B2/en active Active
- 2006-04-28 DK DK19211623.4T patent/DK3670528T3/en active
- 2006-04-28 RS RS20130358A patent/RS52919B/en unknown
- 2006-04-28 EP EP20100014374 patent/EP2325200A1/en not_active Withdrawn
- 2006-04-28 BR BR122020023315-0A patent/BR122020023315B1/en active IP Right Grant
- 2006-04-28 MX MX2007013759A patent/MX2007013759A/en active IP Right Grant
- 2006-04-28 CA CA2947080A patent/CA2947080A1/en not_active Abandoned
- 2006-04-28 ME MEP-2013-358A patent/ME02085B/en unknown
- 2006-04-28 NZ NZ563539A patent/NZ563539A/en unknown
- 2006-04-28 HU HUE10014362A patent/HUE025530T2/en unknown
- 2006-04-28 ES ES06751903T patent/ES2412857T3/en active Active
- 2006-04-28 BR BRPI0610197A patent/BRPI0610197B8/en active IP Right Grant
- 2006-04-28 GE GEAP200612335A patent/GEP20166454B/en unknown
- 2006-04-28 PL PL10014362T patent/PL2325199T3/en unknown
- 2006-04-28 PT PT100143627T patent/PT2325199E/en unknown
- 2006-04-28 GE GEAP200610403A patent/GEP20125594B/en unknown
- 2006-04-28 WO PCT/US2006/016441 patent/WO2006119107A2/en active Application Filing
- 2006-04-28 AU AU2006242431A patent/AU2006242431B2/en active Active
- 2006-04-28 EP EP10008795.6A patent/EP2264063B1/en active Active
- 2006-04-28 RS RS20150373A patent/RS54049B1/en unknown
- 2006-04-28 EA EA200702402A patent/EA021539B1/en not_active IP Right Cessation
- 2006-04-28 NO NO20201120A patent/NO346914B1/en unknown
- 2006-04-28 EP EP20100014375 patent/EP2336163A1/en not_active Withdrawn
- 2006-04-28 CN CN201710738235.4A patent/CN107446043A/en active Pending
- 2006-04-28 KR KR1020147006101A patent/KR101624809B1/en active IP Right Grant
- 2006-04-28 JP JP2008510083A patent/JP5462484B2/en active Active
- 2006-04-28 CN CN201310191210.9A patent/CN103435698B/en active Active
- 2006-04-28 KR KR1020077028092A patent/KR101450888B1/en active IP Right Grant
- 2006-04-28 SG SG10201403400UA patent/SG10201403400UA/en unknown
- 2006-04-28 LT LTEP19211623.4T patent/LT3670528T/en unknown
- 2006-04-28 HR HRP20211904TT patent/HRP20211904T1/en unknown
- 2006-04-28 PL PL19211623T patent/PL3670528T3/en unknown
- 2006-04-28 EP EP21188463.0A patent/EP3985015A1/en active Pending
- 2006-04-28 PT PT192116234T patent/PT3670528T/en unknown
- 2006-04-28 AU AU2006242476A patent/AU2006242476B2/en active Active
- 2006-04-28 SI SI200632414T patent/SI3670528T1/en unknown
- 2006-04-28 KR KR1020157026845A patent/KR101653122B1/en active IP Right Grant
- 2006-04-28 ME MEP-2015-373A patent/ME02247B/en unknown
- 2006-04-28 EP EP10014362.7A patent/EP2325199B1/en not_active Revoked
- 2006-04-28 DK DK10014362.7T patent/DK2325199T3/en active
- 2006-04-28 SI SI200631933T patent/SI2325199T1/en unknown
- 2006-04-28 HU HUE19211623A patent/HUE057097T2/en unknown
- 2006-04-28 RS RS20211488A patent/RS62685B1/en unknown
- 2006-04-28 MX MX2013011425A patent/MX358705B/en unknown
- 2006-04-28 EP EP06751903.3A patent/EP1891101B8/en active Active
- 2006-04-28 CA CA2607197A patent/CA2607197C/en active Active
- 2006-04-28 ES ES10008795.6T patent/ES2689143T3/en active Active
- 2006-04-28 PT PT67519033T patent/PT1891101E/en unknown
- 2006-04-28 EP EP19211623.4A patent/EP3670528B1/en active Active
- 2006-04-28 CN CN200680024330.8A patent/CN101287756B/en active Active
- 2006-04-28 ES ES10014362.7T patent/ES2537278T3/en active Active
- 2006-04-28 MY MYPI20061977A patent/MY163480A/en unknown
- 2006-04-28 KR KR1020137029088A patent/KR20130126752A/en not_active Application Discontinuation
- 2006-04-28 PL PL06751903T patent/PL1891101T3/en unknown
- 2006-04-28 EA EA201400933A patent/EA037044B1/en unknown
- 2006-04-28 NZ NZ591636A patent/NZ591636A/en unknown
- 2006-04-28 ES ES19211623T patent/ES2902548T3/en active Active
- 2006-04-28 UA UAA201202580A patent/UA123695C2/en unknown
- 2006-04-28 DK DK06751903.3T patent/DK1891101T3/en active
- 2006-04-28 SI SI200631623T patent/SI1891101T1/en unknown
- 2006-04-28 CN CN201410042536.XA patent/CN103819558B/en active Active
- 2006-05-02 PE PE2006000459A patent/PE20070317A1/en active IP Right Grant
- 2006-05-02 UY UY0001038207A patent/UY38207A/en active IP Right Grant
- 2006-05-02 UY UY29514A patent/UY29514A1/en not_active Application Discontinuation
- 2006-05-03 GT GT200600186A patent/GT200600186A/en unknown
- 2006-05-03 AR ARP060101798A patent/AR053266A1/en active IP Right Grant
- 2006-05-03 TW TW095115748A patent/TWI494320B/en active
- 2006-05-03 TW TW111132950A patent/TW202323271A/en unknown
- 2006-05-03 TW TW106129848A patent/TWI712613B/en active
- 2006-05-03 TW TW109138424A patent/TWI778444B/en active
- 2006-05-03 TW TW101141376A patent/TW201323438A/en unknown
-
2007
- 2007-10-31 TN TNP2007000406A patent/TNSN07406A1/en unknown
- 2007-11-01 IL IL187106A patent/IL187106A/en active Protection Beyond IP Right Term
- 2007-11-01 MX MX2018005512A patent/MX2018005512A/en unknown
- 2007-11-02 ZA ZA2007/09480A patent/ZA200709480B/en unknown
- 2007-11-15 CR CR9524A patent/CR9524A/en unknown
- 2007-11-23 NO NO20076046A patent/NO345294B1/en active Protection Beyond IP Right Term
- 2007-11-29 MA MA30433A patent/MA29528B1/en unknown
-
2008
- 2008-03-10 HK HK08102741.0A patent/HK1108705A1/en unknown
- 2008-03-10 HK HK11105794.4A patent/HK1151803A1/en unknown
- 2008-11-24 US US12/276,889 patent/US7872106B2/en active Active
-
2010
- 2010-11-19 US US12/950,094 patent/US8383801B2/en active Active
-
2012
- 2012-11-30 US US13/691,344 patent/US9296812B2/en active Active
-
2013
- 2013-01-15 US US13/741,887 patent/US8637643B2/en active Active
- 2013-02-27 IL IL224968A patent/IL224968B/en active IP Right Grant
- 2013-02-27 IL IL224967A patent/IL224967B/en active IP Right Grant
- 2013-07-26 JP JP2013155969A patent/JP5391360B2/en active Active
- 2013-07-26 JP JP2013155968A patent/JP5409952B2/en active Active
- 2013-08-21 CY CY20131100711T patent/CY1114350T1/en unknown
- 2013-08-22 HR HRP20130803TT patent/HRP20130803T1/en unknown
- 2013-11-28 JP JP2013245908A patent/JP5789652B2/en active Active
-
2014
- 2014-11-26 HK HK14111934A patent/HK1198444A1/en unknown
-
2015
- 2015-06-03 CY CY20151100488T patent/CY1116525T1/en unknown
- 2015-06-03 HR HRP20150597TT patent/HRP20150597T1/en unknown
- 2015-08-20 PH PH12015501848A patent/PH12015501848A1/en unknown
-
2016
- 2016-02-15 US US15/043,925 patent/US10562964B2/en active Active
-
2019
- 2019-10-23 US US16/661,669 patent/US11939372B2/en active Active
-
2020
- 2020-03-11 HU HUS2000007C patent/HUS2000007I1/en unknown
- 2020-03-16 LU LU00151C patent/LUC00151I2/fr unknown
- 2020-03-16 NL NL301034C patent/NL301034I2/en unknown
- 2020-04-02 LT LTPA2020506C patent/LTC1891101I2/en unknown
- 2020-05-04 CY CY2020009C patent/CY2020009I2/en unknown
-
2021
- 2021-03-24 NO NO2021014C patent/NO2021014I1/en unknown
- 2021-12-02 CY CY20211101057T patent/CY1124802T1/en unknown
-
2023
- 2023-01-31 NO NO20230084A patent/NO20230084A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04141095A (en) * | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | Hiv-resistant recombined modified antibody and method for preparing modified antibody |
US6057421A (en) * | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
WO2000032773A1 (en) * | 1998-11-27 | 2000-06-08 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
WO2005003158A2 (en) * | 2003-06-16 | 2005-01-13 | Celltech R & D, Inc. | Compositions and methods for increasing bone mineralization |
WO2005014650A2 (en) * | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
Non-Patent Citations (3)
Title |
---|
AVSIAN-KRETCHMER ORNA ET AL: "Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists.", MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) JAN 2004, vol. 18, no. 1, January 2004 (2004-01-01), pages 1 - 12, XP002400896, ISSN: 0888-8809 * |
PATENT ABSTRACTS OF JAPAN vol. 016, no. 413 (C - 0980) 2 September 1992 (1992-09-02) * |
WARMINGTON K ET AL: "Scierostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 19, October 2004 (2004-10-01), & 26TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESE ARCH; SEATTLE, WA, USA; OCTOBER 01 -05, 2004, pages S56 - S57, XP009072609, ISSN: 0884-0431 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006119107A3 (en) | Sclerostin binding agents | |
WO2006119062A3 (en) | Sclerostin epitopes | |
WO2008133722A3 (en) | Anti human sclerostin antibodies | |
WO2008061013A3 (en) | Antibody-based diagnostics and therapeutics | |
TWI370136B (en) | Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses | |
WO2006121422A3 (en) | Antibodies against clostridium difficile toxins and uses thereof | |
WO2008060705A3 (en) | Anti-dll4 antibodies and methods using same | |
WO2007133290A8 (en) | Anti-ox40l antibodies and methods using same | |
EA200702278A1 (en) | ANTIBODIES SPECIFIC FOR TGF-BETA 1 | |
WO2009070243A3 (en) | Wise binding antibodies and epitopes | |
WO2006105152A3 (en) | Amnion-derived cell compositions, methods of making and uses thereof | |
WO2007127317A3 (en) | Humanized c-kit antibody | |
WO2006017538A3 (en) | Hk1-binding proteins | |
WO2009052400A8 (en) | Antibodies that bind to mammalian ngal and uses thereof | |
WO2005100403A3 (en) | Antibodies to erythropoietin receptor and uses thereof | |
WO2007130697A3 (en) | Anti-ephb4 antibodies and methods using same | |
WO2005107491A3 (en) | Multi-lectin affinity chromatography and uses thereof | |
WO2007079218A3 (en) | Metalloproteinase binding proteins | |
EP1836214A4 (en) | Compositions, methods, and kits for enhancing protein expression, solubility and isolation | |
WO2008048519A3 (en) | Antibodies that bind cxcr7 epitopes | |
WO2005081873A9 (en) | Il-13 mutein proteins, antibodies, compositions, methods and uses | |
WO2007127506A3 (en) | Anti-ephrinb2 antibodies and methods using same | |
WO2006116319A3 (en) | Reagents that bind ccx-ckr2 | |
WO2006008266A3 (en) | Factor xi-binding proteins | |
CR20140081A (en) | FIXING AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680024330.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12007502416 Country of ref document: PH Ref document number: 2006242431 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2607197 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013759 Country of ref document: MX Ref document number: 187106 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2008510083 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4223/KOLNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009524 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 563539 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2006242431 Country of ref document: AU Date of ref document: 20060428 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000745 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10403 Country of ref document: GE Ref document number: 1020077028092 Country of ref document: KR Ref document number: 200702402 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: A200713404 Country of ref document: UA Ref document number: 2006751903 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0610197 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12335 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2013/0358 Country of ref document: RS |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137029088 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2014-000081 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147006101 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020157026845 Country of ref document: KR |